0001193125-23-161599.txt : 20230606 0001193125-23-161599.hdr.sgml : 20230606 20230606160556 ACCESSION NUMBER: 0001193125-23-161599 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230605 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230606 DATE AS OF CHANGE: 20230606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLASE, INC CENTRAL INDEX KEY: 0000811240 STANDARD INDUSTRIAL CLASSIFICATION: DENTAL EQUIPMENT & SUPPLIES [3843] IRS NUMBER: 870442441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36385 FILM NUMBER: 23996116 BUSINESS ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 BUSINESS PHONE: 949-361-1200 MAIL ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 FORMER COMPANY: FORMER CONFORMED NAME: BIOLASE TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER MEDICAL TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER ENDO TECHNIC CORP DATE OF NAME CHANGE: 19920708 8-K 1 d492395d8k.htm 8-K 8-K
BIOLASE, INC false 0000811240 --12-31 0000811240 2023-06-05 2023-06-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2023

 

 

BIOLASE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36385   87-0442441

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

27042 Towne Centre Drive, Suite 270
Lake Forest, California 92610
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (949) 361-1200

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   BIOL   The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 3.03.

Material Modification to Rights of Security Holders.

The disclosure set forth in Item 5.03 below is hereby incorporated herein by reference.

 

Item 5.03.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Series I Preferred Stock

On June 5, 2023, the board of directors (the “Board”) of BIOLASE, Inc. (the “Company”), declared a dividend of one one-thousandth of a share of Series I Preferred Stock, par value $0.001 per share (“Preferred Stock”), for each outstanding share of Common Stock to stockholders of record at 5:00 p.m. Eastern Time on June 16, 2023 (the “Record Date”).

General; Transferability. Shares of Series I Preferred Stock will be uncertificated and represented in book-entry form. No shares of Series I Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of Common Stock held by such holder, in which case a number of one one-thousandths (1/1,000ths) of a share of Series I Preferred Stock equal to the number of shares of Common Stock to be transferred by such holder will be automatically transferred to the transferee of such shares of Common Stock.

Voting Rights. Each share of Series I Preferred Stock will entitle the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series I Preferred Stock will have a ratable number of votes). Thus, each one-thousandth of a share of Series I Preferred Stock would entitle the holder thereof to 1,000 votes. The outstanding shares of Series I Preferred Stock will vote together with the outstanding shares of Common Stock of the Company as a single class exclusively with respect to (i) any proposal to adopt an amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to reclassify the outstanding shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment (the “Reverse Stock Split”) and (ii) any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split (the “Adjournment Proposal”). The Series I Preferred Stock will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.

Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split and the Adjournment Proposal, the vote of each share of Series I Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split and the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split will be cast in the same manner as the vote, if any, of the share of Common Stock in respect of which such share of Series I Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of Common Stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series I Preferred Stock (or fraction thereof) held by such holder. Holders of Series I Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series I Preferred Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split.

Dividend Rights. The holders of Series I Preferred Stock, as such, will not be entitled to receive dividends of any kind.

Liquidation Preference. The Series I Preferred Stock will rank senior to the Common Stock as to any distribution of assets upon a liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily (a “Dissolution”). Upon any Dissolution, each holder of outstanding shares of Series I Preferred Stock will be entitled to be paid out of the assets of the Company available for distribution to stockholders, prior and in preference to any distribution to the holders of Common Stock, an amount in cash equal to $0.001 per outstanding share of Series I Preferred Stock.

Redemption. All shares of Series I Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) will automatically be redeemed in whole, but not in part, by the Company at the Initial Redemption Time without further action on the part of the Company or the holder of shares of Series I Preferred Stock (the “Initial Redemption”). Any outstanding shares of Series I Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board in its sole discretion, automatically and effective on such time and date specified by the Board in its sole discretion or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing the Reverse Stock Split.

 

2

Each share of Series I Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $0.01 in cash for each ten whole shares of Series I Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined in the certificate of designation with respect to the Series I Preferred Stock (the “Certificate of Designation”)) thereof as of immediately prior to the applicable redemption time and redeemed pursuant to such redemption. However, the redemption consideration in respect of the shares of Series I Preferred Stock (or fractions thereof) redeemed in any redemption described above: (i) will entitle the former beneficial owners of less than ten whole shares of Series I Preferred Stock redeemed in any redemption to no cash payment in respect thereof and (y) will, in the case of a former beneficial owner of a number of shares of Series I Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of ten, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of ten (such, that for example, the former beneficial owner of 25 shares of Series I Preferred Stock redeemed pursuant to any redemption will be entitled to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 20 shares of Series I Preferred Stock redeemed pursuant to such redemption).

The Series I Preferred Stock is not be convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series I Preferred Stock has no stated maturity and is not subject to any sinking fund. The Series I Preferred Stock is not subject to any restriction on the redemption or repurchase of shares by the Company while there is any arrearage in the payment of dividends or sinking fund installments.

The Certificate of Designation was filed with the Delaware Secretary of State and became effective on June 5, 2023. The foregoing description of the Series I Preferred Stock does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designation, which is filed as Exhibit 3.1 to this Current Report and is incorporated herein by reference.

 

Item 8.01.

Other Events.

On June 5, 2023, the Company issued a press release announcing the Series I Preferred Stock dividend. A copy of that press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed as a part of this Current Report on Form 8-K:

 

Exhibit

No.

    Description
  3.1    Certificate of Designation of the Series I Preferred Stock of the Company, dated June 5, 2023
99.1    Press Release issued by BIOLASE, Inc., dated June 5, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    BIOLASE, INC.
Date: June 6, 2023     By:  

/s/ John R. Beaver

      John R. Beaver
      President and Chief Executive Officer

 

4

EX-3.1 2 d492395dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

BIOLASE, INC.

CERTIFICATE OF DESIGNATION

OF

SERIES I PREFERRED STOCK

Pursuant to Section 151 of the

General Corporation Law of the State of Delaware

THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of BIOLASE, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board of Directors”), in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), acting without the convening of a formal meeting pursuant to Section 141(f) of the DGCL, pursuant to a unanimous written consent of the Board of Directors dated June 5, 2023, which resolution provides for the creation of a series of the Corporation’s Preferred Stock, par value $0.001 per share, which is designated as “Series I Preferred Stock,” with the rights, powers and preferences, and the qualifications, limitations and restrictions thereof, set forth therein.

WHEREAS, the Restated Certificate of Incorporation of the Corporation (as amended, the “Certificate of Incorporation”), provides for a class of capital stock of the Corporation known as preferred stock, consisting of 1,000,000 shares, par value $0.001 per share (the “Preferred Stock”), issuable from time to time in one or more series, and further provides that the Board of Directors is expressly authorized, subject to limitations prescribed by law, to provide for the issuance of the shares of Preferred Stock in one or more series, and by filing a certificate of designation pursuant to the DGCL, to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers (including voting powers), preferences and rights of each such series and the qualifications, limitations or restrictions thereof.

NOW, THEREFORE, BE IT RESOLVED, that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock be, and hereby is, authorized by the Board of Directors, (ii) the Board of Directors hereby authorizes the issuance of 125,000 shares of Series I Preferred Stock and (iii) the Board of Directors hereby fixes the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to all series of the Preferred Stock, as follows:

TERMS OF PREFERRED STOCK

1. Designation, Amount and Par Value. The series of Preferred Stock created hereby shall be designated as the Series I Preferred Stock (the “Series I Preferred Stock”), and the number of shares so designated shall be 125,000. Each share of Series I Preferred Stock shall have a par value of $0.001 per share.

2. Dividends. The holders of Series I Preferred Stock, as such, shall not be entitled to receive dividends of any kind.

3. Voting Rights. Except as otherwise provided by the Certificate of Incorporation or required by law, the holders of shares of Series I Preferred Stock shall have the following voting rights:

3.1. Except as otherwise provided herein, each outstanding share of Series I Preferred Stock shall have 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series I Preferred Stock shall have a ratable number of votes). The outstanding shares of Series I Preferred Stock shall vote together with the outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), of the Corporation as a single class exclusively with respect to the Reverse Stock Split and the Adjournment Proposal (as such terms are defined below) and shall not be entitled to vote on any other matter except to the extent required under the DGCL. Notwithstanding the foregoing, and for the avoidance of doubt, each share of Series I Preferred Stock (or fraction thereof) redeemed pursuant to the Initial Redemption (as defined below) shall have no voting power with respect to, and the holder of each share of Series I Preferred Stock (or fraction thereof) redeemed pursuant to the Initial Redemption shall have no voting power with respect to any such share of Series I Preferred Stock (or fraction thereof) on, the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split. As used herein, the term “Reverse Stock Split” means any proposal to adopt an amendment to the Certificate of Incorporation to reclassify the outstanding shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment; and the term “Adjournment Proposal” means any proposal to adjourn any meeting of shareholders called for the purpose of voting on the Reverse Stock Split.

 

LOGO

 

1

3.2. Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series I Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal shall be cast in the same manner as the vote, if any, of the share of Common Stock (or fraction thereof) in respect of which such share of Series I Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of Common Stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series I Preferred Stock (or fraction thereof) held by such holder. Holders of Series I Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series I Preferred Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split.

4. Rank; Liquidation.

4.1. The Series I Preferred Stock shall rank senior to the Common Stock as to any distribution of assets upon a liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (a “Dissolution”). For the avoidance of any doubt, but without limiting the foregoing, neither the merger or consolidation of the Corporation with or into any other entity, nor the sale, lease, exchange or other disposition of all or substantially all of the Corporation’s assets shall, in and of itself, be deemed to constitute a Dissolution.

4.2. Upon any Dissolution, each holder of outstanding shares of Series I Preferred Stock shall be entitled to be paid out of the assets of the Corporation available for distribution to stockholders, prior and in preference to any distribution to the holders of Common Stock, an amount in cash equal to $0.001 per outstanding share of Series I Preferred Stock.

5. Redemption.

5.1. All shares of Series I Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) shall automatically be redeemed by the Corporation at the Initial Redemption Time without further action on the part of the Corporation or the holder thereof (the “Initial Redemption”).

5.2. Any outstanding shares of Series I Preferred Stock that have not been redeemed pursuant to an Initial Redemption shall be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board of Directors in its sole discretion, automatically and effective on such time and date specified by the Board of Directors in its sole discretion or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing the Reverse Stock Split (any such redemption pursuant to this Section 5.2, the “Subsequent Redemption” and, together with the Initial Redemption, the “Redemptions”). As used herein, the “Subsequent Redemption Time” shall mean the effective time of the Subsequent Redemption, and the “Redemption Time” shall mean (i) with respect to the Initial Redemption, the Initial Redemption Time and (ii) with respect to the Subsequent Redemption, the Subsequent Redemption Time.

5.3. Each share of Series I Preferred Stock redeemed in any Redemption pursuant to this Section 5 shall be redeemed in consideration for the right to receive an amount equal to $0.01 in cash for each ten whole shares of Series I Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined below) thereof as of immediately prior to the applicable Redemption Time and redeemed pursuant to such Redemption, payable upon the applicable Redemption Time; provided, however, that for the avoidance of doubt, the redemption consideration in respect of the shares of Series I Preferred Stock (or fractions thereof) redeemed in any Redemption pursuant to this Section 5: (x) shall entitle the former beneficial owners of less than ten whole shares of Series I Preferred Stock redeemed in any Redemption to no cash payment in respect thereof and (y) shall, in the case of a former beneficial owner of a number of shares of Series I Preferred Stock (or fractions thereof) redeemed pursuant to any Redemption that is not equal to a whole number that is a multiple of ten, entitle such beneficial owner to the same cash payment, if any, in respect of such Redemption as would have been payable in such Redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such Redemption were rounded down to the nearest whole number that is a multiple of ten (such, that for example, the former beneficial owner of 25 shares of Series I Preferred Stock redeemed pursuant to any Redemption shall be entitled to receive the same cash payment in respect of such Redemption as would have been payable to the former beneficial owner of 20 shares of Series I Preferred Stock redeemed pursuant to such Redemption). As used herein, “Person” shall mean any individual, firm, corporation,

 

2

partnership, limited liability company, trust or other entity, and shall include any successor (by merger or otherwise) to such entity. As used herein, a Person shall be deemed the “beneficial owner” of, and shall be deemed to “beneficially own,” any securities which such Person is deemed to beneficially own, directly or indirectly, within the meaning of Rule l3d-3 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended.

5.4. From and after the time at which any shares of Series I Preferred Stock are called for redemption (whether automatically or otherwise) in accordance with Section 5.1 or Section 5.2, such shares of Series I Preferred Stock shall cease to be outstanding, and the only right of the former holders of such shares of Series I Preferred Stock, as such, will be to receive the applicable redemption price, if any. The shares of Series I Preferred Stock redeemed by the Corporation pursuant to this Certificate of Designation shall, upon such redemption, be automatically retired and restored to the status of authorized but unissued shares of Preferred Stock. Notwithstanding anything to the contrary herein or otherwise, and for the avoidance of doubt, any shares of Series I Preferred Stock (or fraction thereof) that have been redeemed pursuant to an Initial Redemption shall not be deemed to be outstanding for the purpose of voting or determining the number of votes entitled to vote on any matter submitted to stockholders (including the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split) from and after the time of the Initial Redemption. Notice of any meeting of stockholders for the submission to stockholders of any proposal to approve the Reverse Stock Split shall constitute notice of (i) a redemption of shares of Series I Preferred Stock pursuant to an Initial Redemption and result in the automatic redemption of the applicable shares of Series I Preferred Stock (and/or fractions thereof) pursuant to the Initial Redemption at the Initial Redemption Time pursuant to Section 5.1 hereof and (ii) a redemption of shares of Series I Preferred Stock pursuant to a Subsequent Redemption and result in the automatic redemption of the applicable shares of Series I Preferred Stock (and/or fractions thereof) pursuant to the Subsequent Redemption at the Subsequent Redemption Time pursuant to Section 5.2 hereof. In connection with the filing of this Certificate of Designation, the Corporation has set apart funds for payment for the redemption of all shares of Series I Preferred Stock pursuant to the Redemptions and shall continue to keep such funds apart for such payment through the payment of the purchase price for the redemption of all such shares.

6. Transfer. Shares of Series I Preferred Stock will be uncertificated and represented in book-entry form. No shares of Series I Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of Common Stock held thereby, in which case a number of one one-thousandths (1/1,000ths) of a share of Series I Preferred Stock equal to the number of shares of Common Stock to be transferred by such holder shall be automatically transferred to the transferee of such shares of Common Stock. Notice of the foregoing restrictions on transfer shall be given in accordance with Section 151 of the DGCL.

7. Fractional Shares. The Series I Preferred Stock may be issued in whole shares or in any fraction of a share that is one one-thousandth (1/1,000th) of a share or any integral multiple of such fraction, which fractions shall entitle the holder, in proportion to such holder’s fractional shares, to exercise voting rights, participate in distributions upon a Dissolution and have the benefit of any other rights of holders of Series I Preferred Stock.

8. Severability. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.

[Remainder of Page Intentionally Left Blank]

 

3

IN WITNESS WHEREOF, Biolase, Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series I Preferred Stock to be duly executed by the undersigned duly authorized officer as of this 5th day of June, 2023.

 

BIOLASE, INC.
By:  

/s/ John R. Beaver

  John R. Beaver
  President and Chief Executive Officer

 

4

EX-99.1 3 d492395dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

BIOLASE ANNOUNCES DISTRIBUTION OF SERIES I PREFERRED STOCK

TO HOLDERS OF ITS COMMON STOCK

Lake Forest, Calif., June 5, 2023 – BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series I Preferred Stock, par value $0.001 per share, for each outstanding share of BIOLASE common stock held of record as of 5:00 p.m. Eastern Time on June 16, 2023. The outstanding shares of Series I Preferred Stock will vote together with the outstanding shares of the Company’s common stock, as a single class, exclusively with respect to a reverse stock split and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series I Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series I Preferred Stock).    

All shares of Series I Preferred Stock that are not present in person or by proxy at the meeting of stockholders held to vote on the reverse stock split as of immediately prior to the opening of the polls at such meeting will automatically be redeemed by BIOLASE. Any outstanding shares of Series I Preferred Stock that have not been so redeemed will be redeemed if such redemption is ordered by BIOLASE’s Board of Directors or automatically upon the effectiveness of the amendment to BIOLASE’s certificate of incorporation effecting the reverse stock split.

The Series I Preferred Stock will be uncertificated, and no shares of Series I Preferred Stock will be transferable by any holder thereof except in connection with a transfer by such holder of any shares of BIOLASE common stock held by such holder. In that case, a number of one one-thousandths of a share of Series I Preferred Stock equal to the number of shares of BIOLASE common stock to be transferred by such holder would be transferred to the transferee of such shares of common stock.

Further details regarding the Series I Preferred Stock will be contained in a Form 8-K to be filed by BIOLASE with the Securities and Exchange Commission on or about the date hereof.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 266 actively patented and 25 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2022, BIOLASE has sold over 45,500 laser systems in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Forward Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s Annual Report on Form 10-K for the year ended December 31, 2022, and other filings made by BIOLASE with the SEC. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

Investor Relations:

EVC Group, Inc.

Michael Polyviou/Todd Kehrli

(732) 232-6914

mpolyviou@evcgroup.com; tkehrli@evcgroup.com

EX-101.SCH 4 biol-20230605.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 biol-20230605_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 biol-20230605_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g492395g14m45.jpg GRAPHIC begin 644 g492395g14m45.jpg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g492395stamp.jpg GRAPHIC begin 644 g492395stamp.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\< M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3H.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( (@ C@,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /?Z "@ H * "@ H 9+-%!$TDTBQQJ,EG. /QH YG4?B1X-T MO N/$5FS'!"P/YS'\$R>U % ?%CPQ/\ \@X:EJ6W[_V33IFV>F1G$,ZL?3 MH#D4 :E !0 4 % !0 4 % !0 4 % !0!EZ]XBTOPSIK7VJW:01#A03\TC?W5 M'5B?04 <7'XE\7:O+%--;P^%],F<"))T\Z_N!Z)'T4_4'&<]J (I_ T_B2[$ M^IVMS)!O#[M9O&FR,<[;>(K&IQW)X_NT ;=IIWA_08_)M]4LK"=6.196]O'A MN_R[&(...: +5U/97@3?J6N)LS_JK:6//UVQC- #C>:4T4=M-KLZ( %,5VB MOZ%A(F??- &3J_P[T/7ECNH+72Y\L':4VX223'I+"5*G@S2X$B#G&6(_'B@"YIGCRZM+Z'3/&&E?V1QOY MEG<'L%D_A)[!J .VCD26-9(W5XV&593D$>H- #J "@ H * "@ H * ..\7^+ MKRPN$T'PU:#4/$=PH*Q_\L[5"<>;*>PYX'>@#$TKPLFHW<6IEVNC'EY==OR' ME%X;016VQ(9DA67B11R9 [X7J"G^T* -%V\6P:!J>JL=E]:Q1WUE; MV\LUQ%*-C!HFW89B=IX'0E2.-[H+6$+>()'#!YYH[ZX^SI(.6>WSRC#/W<=L M8.02 =KX8\3Z;XMT:/4],EW(?EDC;AX7'5&'8B@#9H * "@ H * ./\ &WBR M]TI[?1/#]J+SQ#?J3"A^Y;H.#-(>RC/&>IH I:+HD$=@9[^Z1M(@)>:=R VI MS9PTTI[IG(5.01CJ-HH MR:AJ N[#[18BYGOY&-I8F011VL*@9:0D?,^".,' M!.!C!8@'*V_AS5-7NKZSEU-9;*T9PNH&5F>^BD9U<-+]U3$,@*!PZ*>!0!T= MC ^F0"V\P:C&C1@R/:K!90E3E9.A+-D#Y@6YQ]W' !JZ?:7UY=7\&H:AY4L, MP.RRC\A74J"K$DEB<<9SCY?:@"6[L],M#LWZE//VAAO)W?\ 'Y^![G H IW> MF26VG"2"ZOH]2DSY,+733;6+?+E7+ A<\D=@?:@#3ECU:UB<--;W]OM.\2CR M7"]^1E2<>RCZ4 <:OAQ]1T*ST>WUV^@M\A+:VO$6&:VC*MG'RYD*HVTQM);JZF2&WA4O)(YPJ@=230!YEH4MUXFN[N_MX&M;CQ$RO<>:I_< MZ='E$P.@DDRV,]F)_A% '3ZCJ%N-5@661H+>PEVY7[+;NVV:>3);<['A%X) XZU._@U7P_-#!N66XVQ+'( MNUAO8*&QW7G.1Q@<4 0:;K5O'-?79ANWBN[C>CQ6LCJ%"J@)PO?;GZ$&@"A; M^)4L+!(+>$2ZC,S2W/F.L21N3R?G9>7>S()+J=T M#&,#.%5%)&>I')XYY&* -%;F5["2)[Q+VUN49([M !M8@C:^.!]<#T(!QD @ MN!!K-[IYF9ECNK5@JCAH95*/CZ\<@\#9CO0!7\3:?>:QH4^BZ@OF0R#<6A&! M=JN6\KUC9B%!([9Q@] #G/#]G::9'9ZQ=7L6GW>FLUHUG.V%MK0,45 "-S,0 M%(8D[B>..* .DM0NHZ/]ATJ\C+6P\RPN",A2IQL=3R",A3D9PV>#T ,7PU?Z M?HWB^X40R6D7B)FF99F_U-\AQ+#D]R"&'K@XX(H ]&H * "@#A/'\9UW4M'\ M+E'^PRN;W4Y VU4MH_X6Y_B; _ T :UM=7=OX9N-16U,5U?2@PPLH4Q[RL<0 M89QP-A/XT 2W_@W1=2L[2*[L8)YK.,K!+,F_:>#DCC<,@$@\&@"+2;.)S'I\ M5PTMO8RM-.[X#7,S%F+8'&W<2<^J\?=Y .7M?/M_'LLEW:![T;IKI5ECDDDA MVJL86,,6V!TR!C )SU)H ZFYM+)+O%M=QVYB_?F*>(M&C8SG)^YD9) ],C!! M) ,[3_ _^@P6=SJT\FF1C,-K'(60 D$?,>2/0'.WL: ,^Y\-V-A+]HT&.2\M MS^[:**5I=K]^<_(, =...F2#0 [3+"^LC>10BWDAN4Q=0""-IH1S]X;U !!R M!@@9Y'!R ;L6DP6>G(!J"6UW,DCLQ;S%D0DL05)^< -C=UXZ\XH R8=&CTO3 M[O4$O[K4]7NEG@M)BI'D,01L7.2IRBJ223\@]* -#P^MUJEA+)SG)R1_P$C/(H V_!6MW'B#PG97U[%Y-^ T5U$5VE)D M)5QCMR/UH WZ "@#S62_&N^+=;M8DWQS7EMI.>F4B5II_7^\5/3J.] '4>+] M1LK?2GLKB*XGEN%+)':D"10GS&0%L %=NX9[CC- $5KXCD?095WB75XHU"*R M&+SBYVQOM/W0QQGKM.X=10!$=1A:VLI=-ADGO+&/;/AE B4$"2.0Y^]\IP!S ME<].H!@7ME=0^,+QXM1TM+V*8WS,;O$XC*F-%92,!0I YR,MF@#SJQNK^TU3 MQ'=1:BZ7*ZE: ,2?Q_K$EW;6_]H:5');K M'"KV]F^0!PIPS%Y2*&W^6ZE5V.1(2L:@ M $CA0/3GK0!VOA>\U'2Y[YM7^T?93&LCS3))DS[RI"Y&"&!3 4#D>] %^[O M[][UM0D+6MG;J)+.*0#;=$J<[CC*-@X5<]P2"<@ $NN^+[?3/#7]J6B?:))( MA(B%@@0$@%G)QM52>>_&* )KO3&?P8EK9M/'-! CP,5Q('3##@YYR,8]Z */ MA74[*3Q#K=E:NACN#%J<)0@JR2H%8@C_ &XV)_WJ .NH #P,T >5?"\-J%U% MK!B3;?&^OF9Q\^Z6=%0CL/EB8$#T]Z -?Q:L5WXB"/#=+;11I'=7,%UY;(K" M3 6/:0PVEP22" WR\T 4-/EAUN2QTV>X U6SF^TV%P"#(RAMQCG 'RY YXP? ME8 $8H [66UDN'>.WT]+07$BM>2MM#. !P-N=Q( 7)Z#\J //+.V\[Q9=ES: MW7DS3SW1LII6GDR%C.WY #M*)N"MA>!VY .$MH;9KW789;!IK5=9GWVP8*=@ MD'R@G(! 'TXZ]Z ,]VF\,W4FH6<\PNRCK]HF18U56;89"P=FSM=5S@8+YSA> M0#=L+VUO+U%G.^V72"7 BE,(['"G!88&>.U ' M6^ #GQYK8CL9)I?)MS'(N<1L ^,X]\'G ^7KG (!V7ARPU^X%S:W4M[Y$\*S ME[U6/DW0?>"I8Y*D%/E V@J1P79Q7MC)F>,\4 <-?OI]C80V>I01:N85DDOAQY0D99&CC1B1G:0ZC&3W(W$4 =SX4D M\SPGI+>:TO\ HR#>YRQP,<^_'/O0!PMI$="^*N@[_NWEI>::/W> NR7S4Y'& M2N/RH ]2H 1ONGZ4 >8?!S_D6]'_ .P:W_I3+0!L^(?L+:Q>+)H:WBJL8F9; MADDD9E;:%4<9"J<'(/S'&.<@#?%FJ7ND26NH:6[Q02P_NQ;V?VC[3*3N57"C M<1M#<@C&XGGF@#J$U*"XT%[]ITMXQ 7D?<#Y.%RV2.Z]_I0!Q>A:5$MO+KUK MKD?V9()+6(K:M 82TX>3*T&)[A2?/F&[+*".%7 &,<_$#6)([HV:-% M;JT$@&Z0\XZ9XP2.HY9?H0#T>P&J6_Q G^TFX$=PTF&>11"\05/+5%W$EE.X MDA1]YLYQ0!U&J:C%I5@]W,,JI5<9QR2 .?QH \W?3!9Z]+=O)$;33E@N+:SD MA>X42,'C6-23N+@[",< OT&?^D] 'H] >1B@#ROX7/\ V;+#HCO'OL6O; ECART4 MR.H'8_+,22* -SQ3%:?V\(QI\,LC6LEU#TR#T^E '-#P)*J>5'K,D$)7#Q10_+*0/E+AV M8<'.=N,_@* -.'01I?A^[M((_MDMQ*9Y%8[=[L06/+<#2+=, MM)/*6\Q7^6(8^5>I/S4 +_9/[S?]H/T\ MO_IF4]??- &U\*-.^R^.M:VVOVLA;7,OW#$,-SC/(^4'Z@>U 'K'BGPU_P ) M EF49$FMW.UWSE <992""&& 001T]#0!SIC\2PW*:%);S7UE#*J!YX0\=U"= MI8O(22"N2 .OR\F@"UXGTW2/#UI:W=NAA>*Y2=8D1I2PC!8]_E4 NY/J2>2> M0#HO#6EQZ3HT<$5TMS&[&5957 8-R,5'.1NP02 3U[<@ '0T 4M66V?2YUO)FAMR!O=3@CD4 >#Z3968\3Z MS9ZQ)*-/.KW#3&,[V=#\RY(R<-\N3UP>V<@ ]*TO2/"?B>6[:QMYX98)BTIR M4W[L_-@\8)![#IT% %T?#C05<,IO0?>[=@?P)(H #\-_#[$D_;L^UY(/T!Q0 M!YUK-I!IVOW=E8R3/!$%^6<[F1LD%=W4CC()SUZT 7/AM%:GQ9JUQ-)O^L4?\"% 'L] !0!Q7B*2+5O$<.EVMWBZ$+H%E@+0;MI)0L", M%EW ]1@'/(% &W,X\+^#F**LAL+3"*,*'95PJCIC)P />@#FO!VBO!XSU&XG M8R2:9I]MIJR;B=SD>=*>23R64\T =_0 4 >?_$%_[#UK1/$DJ%M+);3M57&5 M-O+PK-[*^/\ OK'>@#J-!WR:2^GWI6>2T8VTA/(D4 %"?TNXM*M(9"EK#;QJ#._'!R#RS;EPHST.>: +][)HUGI<-[>SSI!.R+&7FD M+;I" !G.>>W3'M0!/9E[_3+BQNPLES;L89"X^5B "K8]P5- 'DWBKP]J6AZ MW!JERT*V^I#R9A'@;9E7Y3PH'S*K#I_" >>2 +X=U*[T37X[FSP_G*RW$6W/ MFHB.X QSN&#C_>/K0!WU_P#$/3;+5OL<,$MW$@_>S0LN(V(R%P2,G!'3IF@" M%/B7IWVF<2V%U%:Q0&8S?*Q.,9&T$GO0!Y=/(\%YJD\SR$0RRAG8'+E9),GG MKGK^- 'IGP^\.:AHNGVZ:E:6Y>13=RRX!=;A\9 YXPOR'V5>N2 =%J%[&VL MVMC).8H0IDD97*$MM;:N01CA9&_X"* (M0\V"P2?1+AIKJ239"LD[2Q2-SD, M23A1@DE>1COT(!0T/0A:ZRK3O,DUJ/,6)V$@PRE05D^\1DN<-SENW)8 F\6W MT=G&MU=R!--TR-K^ZY(WE?\ 5)[Y8$_5!ZT -^'T%\OA2*_U1"FHZG*]].I. M=I<_*OX($'X4 =30 4 5-3TRRUG39].U"W2XM)UVR1N."* /._#U]?>&7N;& M\O/M4FB2"&^W,S-)9,-T,X7U0'#''(4\G H Z36H]06WG&G::NJV=WMFA9+A M5:"3.=XS_#T8%3G.?7( *4L-XLS&Y@MM.D"E[*^N@LS6\8_UBXZ(V,L.2,9! MR%Q0!D>%/$:VUU>V]S>R226,YBDENIM\LP+N"C@(O[Q!&7 7=\AQ[T ='XPT M;3]4T.YNUMEN)IT1%F65QL4L"'!0$\=> ?R)H \INXM5\%7-M+JT5O+&8BB7 M1F9&B$B[0TBKG8^TN,GY,GKD4 +&6EWSS.'DF=I"4^Z,G.U?8=!GG H K7:) M&'FDNC%"4",K':NW.3S[\=>.,=SD Z'0O"MW)<:?J.KV,@L)93MLNORL_]DV\(2%O+(>9B?FV*>6!.Q5]3 MG'!R0#F)M(O?%7BJ#2M5G$EG:*+W5(4(V.[.3;VS#N$ )/\ >X)ZB@#TH# P M.!0 4 % !0!RGB_PU=:C+::WH;QPZ]IQ)A,@^2X0CYH9/]D]O0\T 5/#/B". M"U+3(+>P9SOA;[^FS$G?#+Z)NR5; &#C@;20#KKRT@U"RDMIT62*5<<@$>Q_ MK0!R6F>&$B\0!KBX$,$,OVA-/1"D9EVJN]"#M*?(&V;P\.Z MQ%:60"F1=\\"X6&/) 5F;I&S,<#/#'/UH T+:[T74&GN8Y!#-.IBDWDHV>AX M/!/ &1GH.>!0!D7?PZT+4- 2Q:VLYI-VX7,ELC,>3QD8..?7].* +]KX9T;1 M-66^MQ;62!,>4D:1*3@#MCC@''KS0 V[U_3M$M/L^FP&1GEV(0#Y9=N>&/W^ M"20FXX!Z8X +]SH$%[IEQ;7=U"R@<]@#K9);6PM=TKQ6UO&,98A% M4?R% 'G/B'Q/J]YJ44.AV(FU"X'E:=!,,&!?X[R5?X%QM"!L'K_>Q0!VGACP MY:^&-'2Q@=YYB=]Q=2\R7$AZNYZD_P A@4 ;- !0 4 % !0!Q_BWPG>7MRNO M^&;I=/\ $=NFT2$?N[I/^>4H[CT/44 8V@>*/L&H+IX,D([BU.>3 M 3Q+'U( / Q_=H [8S:=K]I-;17)+#[VPF.6%NQP?F4\<9% '+>(/#FH&'4 M9+;+WER%9)ADQ/*J[5>6-03O5<89>,JI(&T4 .\,6UCIDUK;V\K1)=WMUX1B02S$6\,<+1S*'5A '*]=SH M V?N[QZ4 2KJ/B6V?2Y=*\-P1SF>9KJWM+9$WI'L0H78C:"QEP>IVC ()H K M6?AB'58I4>XMQ(FZ*:!+=I#"\Y\1:KKMWLT&>UOM71BD,4!,EII^1@RS38P\@!("C^]T/6@#I_! MG@ZW\)6,Q:=[W5;QO-OKZ7EYW_HHR<"@#IJ "@ H * "@ H * ,7Q)X6TKQ5 M8K;:E;[GC.Z"=#ME@;J&1NJG('Y1F8E0(]2A?3YQQSRP\MSTZ%>OTR =3H:QIP89!D%SM;Z,P(S[ M9H LQC0;V".X^Q:K>QGYD\^*Y=6]PK\?CCO0!: +M !0 4 % !0 4 % !0 4 % %34-+T_5K?[/J-C;W,./R- '*3_"?PFUP+BQM;C2IAP7T^Z>#(], X_2@"*/X;7,,8CB\=^)UC M7A5^UH<#ZE,T 2K\./,1DO?%WB6[0D$*U_LP?^ 9H FTKX7>#M(V-'HL-S, DASYUV3.Y/U;/Z4 =>JA5"J . !VH 6@ H * "@ H * /__9 end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Jun. 05, 2023
Cover [Abstract]  
Entity Registrant Name BIOLASE, INC
Amendment Flag false
Entity Central Index Key 0000811240
Current Fiscal Year End Date --12-31
Document Type 8-K
Document Period End Date Jun. 05, 2023
Entity Incorporation State Country Code DE
Entity File Number 001-36385
Entity Tax Identification Number 87-0442441
Entity Address, Address Line One 27042 Towne Centre Drive
Entity Address, Address Line Two Suite 270
Entity Address, City or Town Lake Forest
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92610
City Area Code (949)
Local Phone Number 361-1200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol BIOL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 d492395d8k_htm.xml IDEA: XBRL DOCUMENT 0000811240 2023-06-05 2023-06-05 BIOLASE, INC false 0000811240 --12-31 8-K 2023-06-05 DE 001-36385 87-0442441 27042 Towne Centre Drive Suite 270 Lake Forest CA 92610 (949) 361-1200 false false false false Common Stock, par value $0.001 per share BIOL NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d492395d8k.htm 7 d492395d8k.htm biol-20230605.xsd biol-20230605_lab.xml biol-20230605_pre.xml d492395dex31.htm d492395dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d492395d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d492395d8k.htm" ] }, "labelLink": { "local": [ "biol-20230605_lab.xml" ] }, "presentationLink": { "local": [ "biol-20230605_pre.xml" ] }, "schema": { "local": [ "biol-20230605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "biol", "nsuri": "http://www.biolase.com/20230605", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d492395d8k.htm", "contextRef": "duration_2023-06-05_to_2023-06-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d492395d8k.htm", "contextRef": "duration_2023-06-05_to_2023-06-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0001193125-23-161599-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-161599-xbrl.zip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